Neoantigen Targeted Therapies Global Market is Projected to Increase Revenues Growth, Business Insights, Future Demand and Forecast 2024-2033 | Kite Pharma Inc., Gilead Sciences Inc., Amgen Inc., Moderna Inc., BioNTech SE

Overview and Scope
Neoantigen targeted therapies are a type of precision medicine that concentrates on neoantigens in cancer cells. Neoantigens are distinct antigens that are derived from genetic abnormalities or modifications present in cancer cells. It is used to harness the body’s immune system to recognize and attack cancer cells specifically by targeting these neoantigens.

Sizing and Forecast
The neoantigen targeted therapies market size has grown exponentially in recent years. It will grow from $2.43 billion in 2023 to $3.39 billion in 2024 at a compound annual growth rate (CAGR) of 39.3%.  The growth in the historic period can be attributed to advancements in genomic sequencing, immunotherapy evolution, understanding tumor immunology, clinical success of checkpoint inhibitors, molecular profiling advancements.

The neoantigen targeted therapies market size is expected to see exponential growth in the next few years. It will grow to $11.69 billion in 2028 at a compound annual growth rate (CAGR) of 36.3%.  The growth in the forecast period can be attributed to advancements in bioinformatics, precision medicine expansion, neoantigen vaccine development, therapeutic combination strategies, biomarker validation. Major trends in the forecast period include neoantigen resistance management, neoantigen-primed adoptive cell therapies, neoantigen-based combinatorial therapies, integration of real-world data, enhanced predictive models.

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/neoantigen-targeted-therapies-global-market-report

Segmentation & Regional Insights
The neoantigen targeted therapies market covered in this report is segmented –
1) By Type: Monotherapy, Combination Therapy
2) By Immunotherapy Type: DNA Or RNA-Based Vaccines, Protein-Based Vaccines, Dendritic Cell Vaccines, TIL-Based Therapies
3) By Target Disease Indication: Colorectal Cancer, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Bone Cancer, Gynecological Cancer
4) By Route of Administration: Intradermal, Intravenous, Subcutaneous
5) By Application: Medical Research Institution, Hospital, and Clinic, Other Applications

North America  was the largest region in the neoantigen targeted therapies market in 2023. The regions covered in the neoantigen targeted therapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11944&type=smp

Major Driver Impacting Market Growth
The increasing incidence of cancer cases is expected to propel the growth of the neoantigen targeted therapies market going forward. The incidence of cancer refers to the number of new cases of cancer in a specific population for a given period. Neoantigen targeted therapies are often used in combination to treat different types of cancer. For instance, the American Cancer Society (ACS), a US-based voluntary health organization, in 2022, the United States had 1.9 million new cancer cases, representing a significant increase compared to previous years. Furthermore, in 2022, in the US, approximately 609,360 deaths were attributed to cancer, emphasizing the profound severity and impact of this disease on individuals and their families. Therefore, the increasing incidence of cancer cases is driving the growth of the neoantigen targeted therapies market.

Key Industry Players
Major companies operating in the neoantigen targeted therapies market report are F. Hoffmann-La Roche AG, Merck and Co. Inc., Bristol Myers Squibb Company, GlaxoSmithKline plc, Eli Lilly and Company, Kite Pharma Inc., Gilead Sciences Inc., Amgen Inc., Moderna Inc., BioNTech SE, Bavarian Nordic Inc., Advaxis Inc., Immatics NV, Precision Biologics Inc., Iovance Biotherapeutics Inc., Agenus Inc., Achilles Therapeutics Plc, Medigene AG, Gritstone Bio Inc., SQZ Biotechnologies Company, Aduro BioTech Inc., Inovio Pharmaceuticals Inc., Gradalis Inc., EpiVax Inc., ISA Pharmaceuticals BV, Vaxon Biotech SA, Ziopharm Oncology, Genocea Biosciences Inc., Cellular Biomedicine Group Inc., Immunovaccine Inc.

The neoantigen targeted therapies market report table of contents includes:
1. Executive Summary

2. Neoantigen Targeted Therapies Market Characteristics
3. Neoantigen Targeted Therapies Market Trends And Strategies
4. Neoantigen Targeted Therapies Market – Macro Economic Scenario
5. Global Neoantigen Targeted Therapies Market Size and Growth

…..

32. Global Neoantigen Targeted Therapies Market Competitive Benchmarking
33. Global Neoantigen Targeted Therapies Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Neoantigen Targeted Therapies Market
35. Neoantigen Targeted Therapies Market Future Outlook and Potential Analysis
36. Appendix

Explore the trending research reports from TBRC:
https://topprnews.com/gluten-feed-market

https://topprnews.com/organic-feed-market

https://topprnews.com/organic-pigments-market

https://goodprnews.com/rapeseed-oil-market

https://goodprnews.com/gluten-feed-market

https://goodprnews.com/manufactured-soil-market

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc_info

Facebook: https://www.facebook.com/TheBusinessResearchCompany

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Blog: https://blog.tbrc.info

Healthcare Blog: https://healthcareresearchreports.com

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model